Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 April, 2024 09:51 IST
Sun Pharma commences tender offer for acquisition of InSite Vision
Source: IRIS | 29 Sep, 2015, 07.34PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, announced today it has commenced a tender offer through its indirect wholly owned subsidiary, Thea Acquisition Corporation, for all of the outstanding shares of common stock of InSite Vision Incorporated for USD 0.35 a share in cash, without interest and less any required withholding taxes.

The tender offer is being made pursuant to an Offer to Purchase, dated Sep. 29, 2015, and in connection with the previously announced Agreement and Plan of Merger, dated Sep. 15, 2015, as amended and restated as of September 28, 2015, by and among InSite Vision, Ranbaxy, Inc. and Thea Acquisition Corporation.

The tender offer will expire on Oct. 27, 2015, at 12:00 midnight New York City time, unless extended in accordance with the Merger Agreement and the applicable rules and regulations of the Securities and Exchange Commission. Any extension of the tender offer will be followed as promptly as practicable by public announcement thereof, and such announcement will be made no later than 9:00 a.m. New York City time on the next business day after the previously scheduled expiration date.

The tender offer is subject to customary conditions, including the tender of a majority of the outstanding Shares (calculated on a fully-diluted basis). InSite Vision???s board of directors has also approved the transaction and unanimously recommended that its stockholders tender their shares pursuant to the tender offer.

Today, Thea Acquisition Corp. will file with the SEC a tender offer statement on Schedule TO, setting forth in detail the terms of the tender offer. InSite Vision will file today with the SEC a solicitation/recommendation statement on Schedule 14D-9 setting forth in detail, among other things, the recommendation of InSite Vision's board of directors that InSite Vision stockholders accept the tender offer and tender their Shares pursuant to the offer. 

Shares of the company declined Rs 10.4, or 1.21%, to settle at Rs 850.40. The total volume of shares traded was 216,179 at the BSE (Tuesday).

 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer